H.C. Wainwright analyst Oren Livnat has reiterated their bullish stance on ANIP stock, giving a Buy rating on March 14.
Oren Livnat has given his Buy rating due to a combination of factors that suggest positive future performance for ANI Pharmaceuticals. The recent FDA approval for an expanded indication of Iluvien, which now includes chronic non-infectious uveitis affecting the posterior segment, came sooner than anticipated. This approval is expected to facilitate a smoother consolidation of ANI’s ophthalmology franchise, allowing the company to transition more effectively from two products to one, potentially reducing execution risks in 2025.
Additionally, ANI’s strategic moves with Cortrophin Gel, including the launch of a new prefilled syringe, are anticipated to enhance convenience for patients and physicians, thereby driving growth. The merger of ANI’s competitor, Mallinckrodt, with Endo is seen as a favorable development, potentially offering ANI a competitive edge during the integration period. These factors, combined with the potential for increased market share and product uptake, underpin Livnat’s optimistic outlook and the reiterated Buy rating with a high price target.
Livnat covers the Healthcare sector, focusing on stocks such as Avadel Pharmaceuticals, ANI Pharmaceuticals, and Xeris Pharmaceuticals. According to TipRanks, Livnat has an average return of 0.9% and a 43.26% success rate on recommended stocks.
In another report released on March 14, Jefferies also initiated coverage with a Buy rating on the stock with a $80.00 price target.